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METHODS: We applied a state transition model to sim-
ulate the disease progression of heart failure over a period
of 5 years, taking into account a weighted average of cur-
rent practice. Costs related to current practice (1996 val-
ues) and disease progression were taken from the per-
spective of the health insurance. Unit costs of ambulatory
care were collected through official listings; hospitaliza-
tion costs for heart failure were collected from a database
of 58 hospitals (ICD codes 402, 428, 429). Current prac-
tice was obtained through review of 250 patient records
in primary care, starting on the day of initiating therapy
up to 6 months later, and through expert interviews (2
rounds Delphi method).
RESULTS: The model indicates that the expected cost of
treating heart failure in 1996 in Belgium was 318,000 Bef
over 5 years, for an average number of life years of 3.59.
ACE inhibitors are used in 34% of patients but are
mostly applied only in higher NYHA classes (more ill pa-
tients), although studies recommend to prescribe those
drugs earlier in the disease development, since they can
avoid morbidity (hospitalisation) and mortality. We cal-
culated that starting earlier with ACE inhibitors and dou-
bling their use would increase the total costs to 351,700
Bef for an extra survival time of 0.07 life years.
CONCLUSIONS: The study showed that state transition
models can be applied in the assessment of the manage-
ment of heart failure. Changes in the management should
be expressed in extra costs per extra life year and com-
pared to interventions in other disease areas.
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Bolus formulations of new thrombolytic agents for the
treatment of acute myocardial infarction (AMI) may offer
benefits in efficiency of administration, door-to-needle
time, quality improvement, and costs.
METHODS: A telephone survey of 23 experienced emer-
gency room (ER) staff at community and urban hospitals
encompassed the "hassle" involved with thrombolytic
administration. Nurses were asked to compare a hypo-
thetical single bolus with an infusion formulation of rt-PA
under assumptions of equal efficacy and safety. A "has-
sle" analysis examined the differences in aspects such as
protocol complexity, interference with other tasks, poten-
tial for error, and training requirements.
RESULTS: In all aspects, bolus injection was associated
with significantly less hassle than infusion (p < .001). In
particular, bolus injection was perceived as less problem-
atic for nurses in terms of following the protocol, inter-
ference with timely performance of other tasks, distrac-
tion from other tasks, and hassle associated with the
Abstracts
thrombolytic procedure. The results also suggested that
bolus injections may reduce door-to-needle time.
CONCLUSION: A single bolus thrombolytic may offer
promise for improved ease of care, quality patient man-
agement, and incremental reductions in door-to-needle
time. Direct observational studies are needed to more
precisely measure the potential reductions in door-to-nee-
die time using bolus injection.
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In developing an economic model of type 2 diabetes mel-
litus, the costs associated with its complications were ex-
amined. This presentation focuses on the first year costs
associated with acute myocardial infarction (MI).
OBJECTIVE: To estimate the first year costs of initial
acute care (accommodation, procedure and ancillary hos-
pital charges and MD fees) and subsequent care (rehabili-
tation, nursing home, home health care, physician visits,
lab, medications, surgical and invasive cardiovascular
procedures occurring post-discharge) accrued in the man-
agement of MI in diabetic patients.
METHODS: Estimates for these costs were developed
based on data from five all payer, acute care, state dis-
charge databases (CA, FL, MA, MD, NC) and MA long
term care data, using ICD9 codes to identify disease and
procedure level data. These sources were supplemented
by fee schedules, other agency and survey data and the
literature. The proportions of patients consuming each
type of subsequent resource use were estimated from dis-
charge data for each population and published literature.
All costs are reported in 1996 US$, adjusted appropri-
ately for medical inflation and cost-to-charge ratios.
RESULTS: Approximately 31,000 discharges of diabetic
patients with a principal diagnosis of AMI were identi-
fied. The initial hospitalization was 7 days, on average,
with a mean cost of $16,520. The case fatality rate in
hospital was 11 %, and 38% received some type of subse-
quent care post-discharge. Thus, hospitalization ac-
counted for 60% of the total average first year costs
($27,630) accrued.
CONCLUSION: Increased medical management resulting
from an MI, which continues beyond the first year, adds a
substantial cost burden. Avoidance of macrovascular com-
plications should be a key goal of diabetes management.
